Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges in the search for an HIV vaccine.
Lemckert AA, Goudsmit J, Barouch DH. Lemckert AA, et al. Among authors: barouch dh. Eur J Epidemiol. 2004;19(6):513-6. doi: 10.1023/b:ejep.0000032423.87658.68. Eur J Epidemiol. 2004. PMID: 15330122 Review.
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH. Sumida SM, et al. Among authors: barouch dh. J Immunol. 2005 Jun 1;174(11):7179-85. doi: 10.4049/jimmunol.174.11.7179. J Immunol. 2005. PMID: 15905562
Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH. Lemckert AA, et al. Among authors: barouch dh. J Virol. 2005 Aug;79(15):9694-701. doi: 10.1128/JVI.79.15.9694-9701.2005. J Virol. 2005. PMID: 16014931 Free PMC article.
Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH. Nanda A, et al. Among authors: barouch dh. J Virol. 2005 Nov;79(22):14161-8. doi: 10.1128/JVI.79.22.14161-14168.2005. J Virol. 2005. PMID: 16254351 Free PMC article.
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH. Roberts DM, et al. Among authors: barouch dh. Nature. 2006 May 11;441(7090):239-43. doi: 10.1038/nature04721. Epub 2006 Apr 16. Nature. 2006. PMID: 16625206
Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.
Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J. Havenga M, et al. J Gen Virol. 2006 Aug;87(Pt 8):2135-2143. doi: 10.1099/vir.0.81956-0. J Gen Virol. 2006. PMID: 16847108
446 results